Market Size of NTRK Fusion Gene Positive Advanced Solid Tumor Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.40 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis
The NTRK Fusion Gene Positive Advanced Solid Tumor market is anticipated to grow with a CAGR of nearly 5.4%, during the forecast period.
Certain factors that are driving the market growth include increasing prevalence of cancer and growing research and development activities. Globally, cancer is one of the leading causes of death. The disease witnessed significant growth in the last few decades, and it is expected to grow rapidly over the forecast period.
The World Health Organization (WHO) estimates the rate of cancer number to increase by 70% over the next two decades. Additionally, the increased burden of several lifestyle disorders is also expected to drive the market, as biomarkers play a vital role in risk assessment, early diagnosis, and effective monitoring of treatment.
FDA's approval of entrectinib for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors represents a new paradigm in cancer treatment. It treats a cancer based on a common biomarker seen across different tumors rather than based on the location in the body where the cancer originated.
NTRK Fusion Gene Positive Advanced Solid Tumor Industry Segmentation
NTRK gene fusions involving either NTRK1, NTRK2, or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB, and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types. These fusions can be detected in the clinic using a variety of methods, including tumour DNA and RNA sequencing and plasma cell-free DNA profiling. The treatment of patients with NTRK fusion-positive cancers with a first-generation TRK inhibitor, such as larotrectinib or entrectinib, is associated with high response rates.
| By Type | |
| By Therapeutics | |
| By Diagnostics |
| By End-User | |
| Hospitals and Clinics | |
| Cancer Centers | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Summary
The NTRK Fusion Gene Positive Advanced Solid Tumor market is poised for significant expansion, driven by the increasing prevalence of cancer and heightened research and development activities. As cancer remains a leading cause of mortality worldwide, its incidence is expected to rise substantially in the coming years. This surge is further exacerbated by the growing burden of lifestyle-related disorders, which underscores the importance of biomarkers in risk assessment, early diagnosis, and treatment monitoring. The approval of entrectinib by the FDA marks a transformative shift in cancer treatment, focusing on a common biomarker across various tumors rather than the tumor's original location. This approach is supported by multiple methods for identifying NTRK fusions, such as pan-TRK immunohistochemistry and fluorescence in situ hybridization, which have proven effective in clinical settings.
The market landscape is characterized by a competitive environment with key players like Bayer AG, Cephalon, Inc., and F. Hoffmann-La Roche Ltd holding substantial market shares. The regulatory ease in the United States, coupled with funding from organizations like the National Institute of Health, has catalyzed research investments in fusion genes for drug discovery and cancer therapy monitoring. Recent advancements, including the launch of an expanded NTRK RNA fusion reference material panel by SeraCare Life Sciences in collaboration with Bayer, further bolster the market's growth prospects. This dynamic market is supported by ongoing innovations and strategic partnerships, positioning it for continued development and expansion.
NTRK Fusion Gene Positive Advanced Solid Tumor Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Cancer
-
1.2.2 Growing Research and Development Activities
-
-
1.3 Market Restraints
-
1.3.1 Poor Healthcare Infrastructure and High Costs associated with Genetic Screening of NTRK Fusion Genes
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Type
-
2.1.1 By Therapeutics
-
2.1.2 By Diagnostics
-
-
2.2 By End-User
-
2.2.1 Hospitals and Clinics
-
2.2.2 Cancer Centers
-
2.2.3 Others
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
NTRK Fusion Gene Positive Advanced Solid Tumor Market Size FAQs
What is the current NTRK Fusion Gene Positive Advanced Solid Tumor Market size?
The NTRK Fusion Gene Positive Advanced Solid Tumor Market is projected to register a CAGR of 5.40% during the forecast period (2024-2029)
Who are the key players in NTRK Fusion Gene Positive Advanced Solid Tumor Market?
Bayer AG , Empire Genomics, LLC, F. Hoffmann-La Roche Ltd. , NeoGenomics Laboratories, Inc. and OncoDNA are the major companies operating in the NTRK Fusion Gene Positive Advanced Solid Tumor Market.
